108. Optical genome mapping for detection of biomarkers in residual disease monitoring research of hematologic malignancies

Cancer disease monitoring and detection of biomarkers associated with relapse are critical for the appropriate therapeutic management of such diseases. Currently, karyotyping, fluorescent in situ hybridization (FISH), flow cytometry, PCR, and next-generation sequencing are often used for these applications. PCR is sensitive but it's a targeted approach requiring identification of a biomarker. Karyotyping and FISH are used to detect structural variants (SVs); however, karyotype has low sensitivity and FISH is only targeted.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research